Prevalence of statin intolerance: a meta-analysis

I Bytyci, PE Penson, DP Mikhailidis… - European heart …, 2022 - academic.oup.com
Aims Statin intolerance (SI) represents a significant public health problem for which precise
estimates of prevalence are needed. Statin intolerance remains an important clinical …

Statin-associated myopathy

PD Thompson, P Clarkson, RH Karas - Jama, 2003 - jamanetwork.com
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with
skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild …

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

J Shepherd, SM Cobbe, I Ford, CG Isles… - … England Journal of …, 1995 - Mass Medical Soc
Background Lowering the blood cholesterol level may reduce the risk of coronary heart
disease. This double-blind study was designed to determine whether the administration of …

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

SE Nissen, EM Tuzcu, P Schoenhagen, BG Brown… - Jama, 2004 - jamanetwork.com
ContextStatin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and
mortality. However, the optimal strategy and target level for lipid reduction remain uncertain …

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

SE Nissen, SJ Nicholls, I Sipahi, P Libby, JS Raichlen… - Jama, 2006 - jamanetwork.com
ContextPrior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of
atherosclerosis progression with statin therapy but have not shown convincing evidence of …

Intensive lifestyle changes for reversal of coronary heart disease

D Ornish, LW Scherwitz, JH Billings, KL Gould… - Jama, 1998 - jamanetwork.com
Context.—The Lifestyle Heart Trial demonstrated that intensive lifestyle changes may lead to
regression of coronary atherosclerosis after 1 year. Objectives.—To determine the feasibility …

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

SE Nissen, T Tsunoda, EM Tuzcu, P Schoenhagen… - Jama, 2003 - jamanetwork.com
Context Although low levels of high-density lipoprotein cholesterol (HDL-C) increase risk for
coronary disease, no data exist regarding potential benefits of administration of HDL-C or an …

Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies* on Coronary …

D Wood, G De Backer, O Faergeman… - Journal of …, 1998 - journals.lww.com
Since the first Joint European Societies (European Society of Cardiology, European
Atherosclerosis Society and European Society of Hypertension) Task Force …

Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials

PR Hebert, JM Gaziano, KS Chan, CH Hennekens - Jama, 1997 - jamanetwork.com
Objective.—To examine whether cholesterol lowering with 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors (statin drugs) reduces the risks of stroke and …

A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis

SJ Cowell, DE Newby, RJ Prescott… - … England Journal of …, 2005 - Mass Medical Soc
Background Calcific aortic stenosis has many characteristics in common with
atherosclerosis, including hypercholesterolemia. We hypothesized that intensive lipid …